Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication

This article has been Reviewed by the following groups

Read the full article

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2020.06.24.150326: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Biosafety and IRB Approval: Appropriate institutional review boards (IRB) approvals were obtained at UCLA and Cedars-Sinai Medical Center
    Randomizationnot detected.
    BlindingThree to five images per well were quantified for each condition using Image J’s plugin Cell Counter feature was used to count the positively stained cells by a double blinded approach.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    48 hpi, the cells were fixed and immunostained with anti-dsRNA antibody (J2 clone; Absolute Antibody Inc, USA) to assess viral genome replication (Figure 1C).
    anti-dsRNA
    suggested: (Millipore Cat# MABE1134, RRID:AB_2819101)
    Experimental Models: Cell Lines
    SentencesResources
    ACE2 entry receptor overexpressing human embryonic kidney 293T cells (293T-ACE2) were established and cultured in the media described above with the presence of puromycin (1 µg/ml).
    293T
    suggested: RRID:CVCL_YZ65)
    SARS-CoV-2 was passaged once in Vero-E6 cells and viral stocks were aliquoted and stored at -80°C.
    Vero-E6
    suggested: None
    The spent media from each well was removed and 100 µl of prepared inoculum was added onto Vero cells.
    Vero
    suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
    Software and Algorithms
    SentencesResources
    Image Analysis/Quantification: Microscope images were obtained using the Leica DM IRB and Zeiss Software Program.
    Zeiss Software Program
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.